Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On October 3, 2025, Tiziana Life Sciences announced its interim financial results for the first half of 2025, highlighting significant progress in its clinical programs. The company reported advancements in its Phase 2 trials for intranasal foralumab, particularly in treating non-active Secondary Progressive Multiple Sclerosis and Multiple System Atrophy. The FDA’s Fast Track designation for foralumab underscores its potential in addressing unmet medical needs. Tiziana’s financial management remains disciplined, with non-dilutive funding strengthening its balance sheet, allowing continued investment in promising programs. The expansion to Boston aims to enhance clinical trial execution and collaboration within the neuroscience and immunology sectors.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a biotechnology company focused on developing innovative immunomodulation therapies. Their primary product in development is intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, aimed at treating neurodegenerative and autoimmune diseases. The company is strategically expanding its presence in the U.S., with a new office in Boston, Massachusetts, to leverage the region’s vibrant biotechnology ecosystem.
Average Trading Volume: 400,408
Technical Sentiment Signal: Buy
Current Market Cap: $217.4M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.
